Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $22.78 Consensus Price Target from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been assigned a consensus rating of "Hold" from the nine ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $22.78.

PCRX has been the topic of a number of analyst reports. Needham & Company LLC increased their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays dropped their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a report on Tuesday, November 12th. HC Wainwright restated a "buy" rating and issued a $39.00 target price on shares of Pacira BioSciences in a report on Wednesday, December 4th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th.

Pacira BioSciences Stock Performance

Pacira BioSciences stock traded down $1.09 during trading hours on Thursday, reaching $25.44. 615,935 shares of the stock were exchanged, compared to its average volume of 924,745. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $31.67. The stock has a 50 day moving average of $22.00 and a two-hundred day moving average of $18.15.

Institutional Investors Weigh In On Pacira BioSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC increased its position in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after acquiring an additional 1,208 shares in the last quarter. Caitlin John LLC increased its position in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after acquiring an additional 513 shares in the last quarter. Finally, CWM LLC increased its position in shares of Pacira BioSciences by 713.6% during the third quarter. CWM LLC now owns 6,517 shares of the company's stock worth $98,000 after acquiring an additional 5,716 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.